Search Results

1 - 10 of 321 items :

  • "dyslipidemia" x
Clear All
Epidemiology of Dyslipidemia Among Adult Population of Bangladesh

33(4):138–141, 2008. 4. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: A systematic review. Atherosclerosis 196(2): 489–496, 2008. 5. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 102(10S):1K–34K, 2008. 6. Bhalodkar NC, Blum S, Rana T, Bhalodkar A, Kitchappa R, Kim KS, et al. Comparison of levels of large and

Open access
HbA1c as a Predictor of Dyslipidemia in Algerian Type 2 Diabetic Patients

diabetes. Ann Cardiol Angeiol (Paris) 61: 81-87, 2012. 11. Mullugeta Y, Chawla R, Kebede T, Worku Y. Dyslipidemia associated with poor glycemic control in type 2 diabetes mellitus and the protective effect of metformin supplementation. Ind J Clin Biochem 27: 363–369, 2012. 12. Beckman JA, Creager MA, Libby P . Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287: 2570-2581, 2002. 13. Meerwaldt R, Links T, Zeebregts C, Tio R, Hillebrands JL, Smit A. The clinical relevance of assessing advanced glycation

Open access
Prevalence of Dyslipidemia and Its Association with Glycemic Control in Indian Type 2 Diabetes Population

dyslipidemia. Atherosclerosis Suppl 3: 47-51, 2002. 5. Cade WT . Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther 88: 1322-1335, 2008. 6. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs 73: 327-39, 2013. 7. Haffner S, American Diabetes Association . Management of dyslipidemia in adults with diabetes. Diabetes Care 26(suppl 1): S83-S86, 2003. 8. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population

Open access
Apolipoproteins: Good Markers for Cardiovacular Risk in Patients with Chronic Kidney Disease and Dyslipidemia

References 1. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol Renal Physiol 290: F262-72, 2006. 2. Yamamoto S, Kon V. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr Opin Nephrol Hypertens 18: 181-8, 2009. 3. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 356: 147-52, 2000. 4. Eknoyan G, Lameire N, Eckardt K-U et al. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney

Open access
Is Non Dipping Hypertension Associated with Dyslipidemia, Type 2 Diabetes or Chronic Kidney Disease?

References 1. Papadopoulos D, Mourouzis I, Faselis C et al. Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich) 15: 333-336, 2013. 2. Battleman DS, Peterson ED . Estimated prevalence of comorbid hypertension and dyslipidemia and therapeutic goal attainment among US adults in 2000, utilizing data from the National Health and Nutrition Examination Survey (NHANES III). J Manag Care Pharm 10: 186, 2004. (Abstract) 3. Blank R, LaSalle J

Open access
Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (The Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity

List of abbreviations OS, oxidative stress DOI, dyslipidemia, oxidative stress, inflammation CG, control group References 1. Collinson P. Laboratory medicine is faced with the evolution of medical practice. J Med Biochem 2017; 36: 211–5. 2. Macut D, Bačević M, Božić-Antić I, Bjekić-Macut J, Čivčić M, Erceg S et al. Predictors of subclinical cardiovascular disease in women with PCOS: interrelationship of dyslipidemia and arterial blood pressure. Int J Endocrinol 2015; 2015: 1–9. 3. Macut D, Bjekić-Macut J, Savić-Radojević A

Open access
Decreased serum level of gamma-amino butyric acid in Egyptian infertile females with polycystic ovary syndrome is correlated with dyslipidemia, total testosterone and 25(OH) vitamin D levels

hyperandrogenism and polycystic ovaries on ultrasound examination ( 4 ). PCOS patients suffered from severe manifestations as infertility, hirsutism, acne, alopecia and disturbed hormonal profile. ( 5 , 6 ). Moreover, PCOS is highly combined with insulin resistance (IR) ( 7 , 8 ), dyslipidemia ( 6 , 9 ) and obesity ( 10 ). Heterogenic factors further contribute to PCOS manifestations ( 11 ). PCOS was believed to be a mere ovarian disorder. Nevertheless, increasing basic and clinical research imply that disruption in the neuroendocrine homeostasis of the hypothalamus

Open access
Glycemic Status in Patients with Polycystic Ovary Syndrome and Dyslipidemia Before and After Three Months Treatment with Atorvastatin

Abstract

Background and Aims. Polycystic ovary syndrome (PCOS) is associated with disturbances in carbohydrate and lipid metabolism. Statins appear to have beneficial effects in PCOS, although some meta-analyzes showed an increased risk of developing diabetes mellitus. The aim of this study was to evaluate the effect of treatment with 20 mg of atorvastatin daily for three months on glucose tolerance in a group of 8 normal weight patients with PCOS and dyslipidemia. Material and Methods. We evaluated 8 patients aged between 29 and 40 years, with normal weight, diagnosed with PCOS and dyslipidemia. The carbohydrate metabolism was assessed by oral glucose tolerance test (OGTT) before and after 3 months of therapy with 20 mg of atorvastatin daily. Results. Treatment with atorvastatin resulted in a statistically significant reduction in total cholesterol (p = 0.001), LDL cholesterol (p = 0.001), triglycerides (p = 0.01) and statistically significant increase in HDL cholesterol (p = 0.003). Fasting plasma glucose (p = 0.59) and the 2-hour OGTT glycemia (p = 0.54) were not significantly changed. Total testosterone decreased significantly ( p= 0.04). Conclusions. At baseline, all patients included in our study showed unaffected carbohydrate metabolism. Even after 3 months of therapy with atorvastatin 20 mg daily no changes in glucose homeostasis were noted.

Open access
Dyslipidemia in subclinical hypothyroidism requires assessment of small dense low density lipoprotein cholesterol (sdLDL-C)

Abstract

Background. Usually both hypothyroidism and hyperthyroidism are related to the cardiovascular and cerebrovascular disease development. The relationship between subclinical hypothyroidism has been widely investigated but the findings remain controversial. The aim of the present study was to evaluate the lipid profile in patients with subclinical hypothyroidism (SHypo) in comparison to controls and to determine the association of SHypo and dyslipidemia in attempt to find importance of small dense low-density lipoprotein cholesterol (sdLDL-C) in atherosclerosis. Material and methods. In this study we included 100 women, aged 30 to 70 years that were divided into subgroups according to their age. According to the values of levels of thyroid hormones they were divided into euthyroid (control) group (n = 64) and (newly discovered) subclinical hypothyroidism (SHypo) group (n = 36). A high-sensitivity C-reactive protein (hs-CRP) and lipid profile, including small dense low-density lipoprotein cholesterol (sdLDL-C) were determined. Body weight and height were measured and BMI calculated. History of the current illness, medication, alcohol consumption and cigarettes smoking were noted. Results. Changed lipid profile as well as elevated triglycerides and sdLDL-C were observed in the group with subclinical hypothyroidism compared to the control group. Conclusions. It is important to determine serum lipid levels, especially serum sdLDL-C levels at an early stage of subclinical hypothyroidism, since they represent atherogenic LDL particles and are better indicators for dyslipidaemia in subclinical hypothyroidism and the development of atherosclerosis with potential complications such as cardiovascular and cerebrovascular diseases.

Open access
Abnormal lipid metabolism in metabolic syndrome: an epigenetic perspective

;45:149-57. 6. Frazier-Wood AC, Aslibekyan S, Absher DM, Hopkins PH, Sha J, Tsai MY, et al. Methylation at CPT1A locus is associated with lipoprotein subfraction profiles. J Lipid Res. 2014;55(7):1324-30. DOI: 10.1194/jlr.M048504. 7. Mendelson M, Liang L, Chen J, Baccarelli A, Hirschhorn JN, S.K. Osganian SK, de Ferranti SD. Epigenetic modifications associated with dyslipidemia among obese children and adolescents. CJC. 2014;30(10):S190-1. 8. Mamtani M, Kulkarni H, Dyer T, Göring HH, Neary JL, Cole SA, et al. Genome- and epigenome

Open access